Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0033-3158 (Print) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE

Original Publication: Berlin, New York, Springer-Verlag.

Hot Temperature*; Brain/*drug effects ; Central Nervous System Depressants/*adverse effects ; Ethanol/*adverse effects ; N-Methyl-3,4-methylenedioxyamphetamine/*toxicity ; Neurotoxicity Syndromes/*metabolism ; Serotonin/*metabolism ; Serotonin Agents/*toxicity; Acetaldehyde/metabolism ; Alcoholic Intoxication/complications ; Aldehyde Dehydrogenase/antagonists & inhibitors ; Animals ; Body Temperature/drug effects ; Brain/metabolism ; Central Nervous System Depressants/administration & dosage ; Central Nervous System Depressants/blood ; Central Nervous System Depressants/metabolism ; Cyanamide/pharmacology ; Drug Interactions ; Enzyme Inhibitors/pharmacology ; Ethanol/administration & dosage ; Ethanol/blood ; Ethanol/metabolism ; Fever/chemically induced ; Fever/metabolism ; Hydroxyl Radical/metabolism ; Inhalation Exposure ; Male ; Neurotoxicity Syndromes/complications ; Neurotoxicity Syndromes/physiopathology ; Rats ; Serotonin Plasma Membrane Transport Proteins/metabolism ; Serotonin Syndrome/metabolism ; Time Factors

Rationale: Ecstasy abuse commonly occurs in hot, overcrowded environments in combination with alcohol. Around 90% of ecstasy users take ethanol; over 70% of these users also often drink alcohol at hazardous levels.
Objectives: We wished to examine whether binge ethanol administration enhanced the long-lasting 5-HT neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats maintained at high ambient temperature and the role of acetaldehyde.
Materials and Methods: Rats were treated with a 4-day ethanol regimen leading to plasma ethanol levels of around 450 mg/dl. On day 5, rats were placed at 30 degrees C and administered MDMA (5 mg/kg). Rectal temperature and hydroxyl radical formation were measured immediately before and up to 6 h after MDMA. 5-HT concentration and 5-HT transporter density were determined 7 days later. A group of rats received cyanamide (50 mg/kg) on days 1 and 3 of the 4-day-ethanol inhalation.
Results: In ethanol treated rats, MDMA produced a hyperthermic response similar to that observed in controls but enhanced the loss of 5-HT concentration and 5-HT transporter density in the hippocampus. Cyanamide elevated the plasma acetaldehyde concentration fivefold to sevenfold, reduced the MDMA-induced hyperthermia and increased the neuronal damage with neurotoxicity also appearing in the cortex. MDMA increased hydroxyl radical production in the hippocampus, the effect being more marked in rats pre-exposed to ethanol.
Conclusions: Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity by a mechanism not related to changes in acute hyperthermia but probably involving hydroxyl radical formation. The magnitude of this effect is more pronounced after increasing plasma acetaldehyde levels by aldehyde dehydrogenase inhibition.

Comment in: Psychopharmacology (Berl). 2007 Mar;190(4):581-2. (PMID: 17235607)
Comment in: Psychopharmacology (Berl). 2007 Apr;191(2):387-8. (PMID: 17265072)

Br J Pharmacol. 1997 Jun;121(4):827-33. (PMID: 9208155)
Free Radic Biol Med. 1991;10(6):439-41. (PMID: 1654291)
J Stud Alcohol. 2000 Sep;61(5):647-51. (PMID: 11022801)
Physiol Behav. 1987;40(4):411-24. (PMID: 3628538)
Alcohol Clin Exp Res. 2001 Jul;25(7):982-8. (PMID: 11505022)
Biochem Pharmacol. 1976 Dec 15;25(24):2733-7. (PMID: 1008896)
Brain Res Bull. 1981 Aug;7(2):209-20. (PMID: 6974036)
Drug Alcohol Depend. 2003 Dec 11;72(3):225-35. (PMID: 14643939)
J Pharmacol Exp Ther. 1979 Jan;208(1):128-33. (PMID: 759607)
Psychol Rep. 2004 Aug;95(1):192-6. (PMID: 15460375)
Am J Psychiatry. 1995 Mar;152(3):332-40. (PMID: 7864257)
Alcohol. 1996 Nov-Dec;13(6):603-10. (PMID: 8949956)
Psychopharmacology (Berl). 2001 Jan 1;153(2):196-202. (PMID: 11205419)
Drug Alcohol Depend. 2001 Sep 1;64(1):9-17. (PMID: 11470336)
J Neurochem. 1995 Apr;64(4):1819-25. (PMID: 7891110)
Alcohol Clin Exp Res. 2004 Feb;28(2):350-64. (PMID: 15112943)
Int J Neurosci. 2003 Dec;113(12):1643-52. (PMID: 14602538)
Alcohol. 1993 Nov-Dec;10(6):559-61. (PMID: 8123218)
J Biol Chem. 1989 May 15;264(14):7761-4. (PMID: 2542241)
J Pharmacol Exp Ther. 1995 May;273(2):667-73. (PMID: 7538579)
Neurosci Lett. 1993 Sep 3;159(1-2):83-7. (PMID: 7505417)
Neuropharmacology. 1994 Dec;33(12):1589-95. (PMID: 7539115)
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Aug;27(5):819-27. (PMID: 12921915)
Synapse. 1999 Mar 1;31(3):169-77. (PMID: 10029234)
Alcohol Clin Exp Res. 2001 Jul;25(7):976-81. (PMID: 11505021)
J Chromatogr Sci. 2002 Oct;40(9):477-82. (PMID: 12433107)
Psychopharmacology (Berl). 1991;105(1):113-8. (PMID: 1684057)
Brain Res. 2002 Jul 19;944(1-2):90-6. (PMID: 12106669)
J Neurochem. 1970 Dec;17(12):1677-87. (PMID: 5492987)
Pharmacol Biochem Behav. 2002 Jun;72 (3):521-32. (PMID: 12175448)
Alcohol Alcohol. 2002 Sep-Oct;37(5):432-5. (PMID: 12217933)
Pharmacol Rev. 2003 Sep;55(3):463-508. (PMID: 12869661)
J Pharmacol Exp Ther. 1992 May;261(2):616-22. (PMID: 1374470)
Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1019-23. (PMID: 8302826)
Stroke. 2002 Mar;33(3):790-4. (PMID: 11872905)
Drug Alcohol Depend. 2005 Jun 1;78(3):317-23. (PMID: 15893163)
J Pharmacol Exp Ther. 2005 Aug;314(2):780-8. (PMID: 15878999)
Alcohol Clin Exp Res. 2002 Apr;26(4):547-57. (PMID: 11981132)
Lab Invest. 1982 Nov;47(5):412-26. (PMID: 6290784)
Neurotoxicology. 1999 Dec;20(6):977-87. (PMID: 10693979)
Acad Emerg Med. 2000 Jan;7(1):14-20. (PMID: 10894237)
Psychopharmacology (Berl). 2005 Oct;182(2):262-76. (PMID: 16010539)
FASEB J. 1998 Feb;12(2):221-30. (PMID: 9472987)
Br J Psychol. 2000 May;91 ( Pt 2):181-8. (PMID: 10832513)
Prog Neurobiol. 1998 Nov;56(4):385-431. (PMID: 9775400)
Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):15S-32S. (PMID: 11391045)
J Neurochem. 1991 Jan;56(1):1-11. (PMID: 1987314)
Br J Pharmacol. 1994 May;112(1):188-94. (PMID: 8032640)
Psychopharmacology (Berl). 2000 Feb;148(3):322-4. (PMID: 10755746)
J Neurochem. 2004 Jun;89(6):1445-53. (PMID: 15189347)
Alcohol Res Health. 2003;27(2):186-96. (PMID: 15303630)
Exp Neurol. 2005 Jul;194(1):175-81. (PMID: 15899254)
Psychopharmacology (Berl). 2005 Aug;180(4):607-11. (PMID: 15372137)
Eur J Pharmacol. 1995 Jul 14;280(3):343-6. (PMID: 8566105)
Br J Pharmacol. 2001 Sep;134(1):46-57. (PMID: 11522596)
Eur J Pharmacol. 1999 Dec 3;385(2-3):103-10. (PMID: 10607865)
Eur J Pharmacol. 2005 Sep 27;520(1-3):51-8. (PMID: 16135364)
J Neurosci. 1988 Aug;8(8):2788-803. (PMID: 2457659)
Hum Psychopharmacol. 2003 Jun;18(4):281-90. (PMID: 12766933)
Free Radic Biol Med. 1992 Nov;13(5):581-3. (PMID: 1334031)
Trends Pharmacol Sci. 2004 Mar;25(3):130-4. (PMID: 15019267)
Brain Res. 2003 Jul 18;978(1-2):115-23. (PMID: 12834905)
Neurology. 1998 Dec;51(6):1532-7. (PMID: 9855498)
Clin Chim Acta. 2003 Jul 1;333(1):69-77. (PMID: 12809737)
Hippocampus. 2000;10(3):284-95. (PMID: 10902898)
Hum Psychopharmacol. 2004 Jun;19(4):225-34. (PMID: 15181650)
Alcohol Clin Exp Res. 1992 Jun;16(3):539-41. (PMID: 1320808)
Psychopharmacology (Berl). 2004 May;173(3-4):391-7. (PMID: 14735294)
Neuroscience. 2004;124(4):869-77. (PMID: 15026127)
J Biol Chem. 1951 Nov;193(1):265-75. (PMID: 14907713)
Biochem Pharmacol. 1992 Jul 7;44(1):93-8. (PMID: 1632841)
Alcohol Clin Exp Res. 1996 Apr;20(2):284-92. (PMID: 8730219)
J Pharmacol Exp Ther. 1987 Sep;242(3):911-6. (PMID: 2443644)
Arch Gen Psychiatry. 1998 Oct;55(10):905-12. (PMID: 9783561)
Resuscitation. 1996 Oct;32(3):199-202. (PMID: 8923581)
Phytother Res. 2003 Aug;17 (7):737-43. (PMID: 12916070)
Drug Alcohol Depend. 1998 Sep 1;52(1):85-90. (PMID: 9788011)
Psychopharmacology (Berl). 2002 Jul;162(2):203-14. (PMID: 12110998)
Alcohol Alcohol. 1996 Jul;31(4):403-10. (PMID: 8879290)
J Lipid Res. 1994 Mar;35(3):428-37. (PMID: 8014578)
Br J Pharmacol. 1997 Jul;121(5):889-900. (PMID: 9222545)

0 (Central Nervous System Depressants)
0 (Enzyme Inhibitors)
0 (Serotonin Agents)
0 (Serotonin Plasma Membrane Transport Proteins)
333DO1RDJY (Serotonin)
3352-57-6 (Hydroxyl Radical)
3K9958V90M (Ethanol)
420-04-2 (Cyanamide)
EC 1.2.1.3 (Aldehyde Dehydrogenase)
GO1N1ZPR3B (Acetaldehyde)
KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)

Date Created: 20061019 Date Completed: 20070302 Latest Revision: 20181113

20231215

10.1007/s00213-006-0602-1

17047928